C2N Diagnostics is set to develop blood biomarkers for the early identification of Alzheimer’s disease.
A recent study found that the brain protein tau phosphorylated at position 217 (p-tau217) is measurable in blood by mass spectrometry and this form of tau is a significant early indicator of Alzheimer’s disease.
C2N scientific co-founder Dr Randall Bateman, along with collaborators from the Department of Neurology at Washington University School of Medicine in St Louis in the US, has developed the novel mass spectrometry methods to quantify both total tau and multiple phosphorylated tau isoforms.
The company revealed it has acquired the exclusive global commercial rights to the intellectual property associated with the blood biomarkers and will develop them for clinical diagnostic applications.
C2N CEO Dr Joel Braunstein said: “C2N has extensive experience commercialising mass spectrometry assays, and we plan to optimise this assay to make it available for broad use.
“The ability to measure novel markers like p-tau217 in blood could markedly enhance the ability to identify and follow the disease at its earliest stages. Earlier detection likely means earlier intervention, which includes making it easier for patients to participate in clinical trials for prevention and treatment.”
C2N is currently developing comprehensive Brain Health Panel that will measure multiple features of Alzheimer’s disease and related disorders.
The new p-tau test is expected to complement the company’s Aβ test, which is scheduled to reach physicians’ offices in the next few months.
Separately, Eli Lilly and Company reported positive outcomes of its P-tau217 blood test for Alzheimer’s disease in a new study.
The study found that P-tau217 distinguished the disease from other neurodegenerative diseases significantly better than other blood-based biomarkers or magnetic resonance imaging (MRI).
The company, along with its wholly owned subsidiary Avid Radiopharmaceuticals, is studying P-tau217 as a biomarker of Alzheimer’s disease pathology.